Leah Umfrey, MD
Glaucoma Specialist · Albany, NYNPI 1972035681
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 155 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 28.1% of the total. 2025 is the largest year on record at $2,447, more than ten times the $24 reported in 2019.
Across 155 payments — averaging $37.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$2K
- Sight Sciences, Inc.$1K
- Alcon$863
- Mallinckrodt Hospital Products Inc.$400
- Tarsus Pharmaceuticals, Inc.$247
- AbbVie$225
- plus $1K from 14 others
Across 1 payment — averaging $6500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$7K
What the payments were for
- Food & beverage$5,78199%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 42 | $1,633 |
| Sight Sciences, Inc. | 26 | $1,306 |
| Alcon | 25 | $863 |
| Mallinckrodt Hospital Products Inc. | 9 | $400 |
| Tarsus Pharmaceuticals, Inc. | 11 | $247 |
| AbbVie(2 entities) | 8 | $225 |
| Biotissue Holdings Inc. | 2 | $185 |
| Sun Pharmaceutical Industries Inc. | 8 | $177 |
| Dompe US, Inc. | 5 | $138 |
| Oyster Point Pharma, Inc. | 2 | $114 |
| Apellis Pharmaceuticals, Inc. | 1 | $109 |
| Ocular Therapeutix, Inc. | 5 | $98 |
| Astellas Pharma US Inc | 3 | $92 |
| Rxsight Inc | 1 | $88 |
| NEW World Medical,inc. | 2 | $44 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| Aerie Pharmaceuticals, Inc. | 1 | $24 |
| Rayner Intraocular Lenses Limited | 1 | $21 |
| Lensar, Inc. | 1 | $19 |
| Alimera Sciences, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$865
- enVista MX60 IOL$745
- SION SURGICAL INSTRUMENT$487
- ENVISTA ENVY IOL$340
- Clareon$256
- STELLARIS$144
- ACTHAR$126
- VYZULTA$125
- Rhopressa$125
- Rocklatan$125
- XDEMVY$122
- IC-8 Apthera IOL$117
- Syfovre$109
How this compares
$5,821 in reported general payments places this provider in the 80th percentile of 35 glaucoma specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 34 | $58,632 |
| Cyclosporine | 58 | $33,418 |
| LumiganBimatoprost | 60 | $28,324 |
| XiidraLifitegrast | 15 | $18,363 |
| VyzultaLatanoprostene Bunod | 40 | $16,134 |
| RhopressaNetarsudil Mesylate | 34 | $14,663 |
| RocklatanNetarsudil Mesylat/Latanoprost | 25 | $14,533 |
| Bromfenac Sodium | 74 | $12,001 |
| Prednisolone Acetate | 353 | $11,227 |
| Latanoprost | 988 | $10,786 |
| TyrvayaVarenicline Tartrate | 14 | $10,377 |
| MieboPerfluorohexyloctane/Pf | 12 | $10,222 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 47 | $10,080 |
| CombiganBrimonidine Tartrate/Timolol | 30 | $7,693 |
| ProlensaBromfenac Sodium | 20 | $7,019 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $225 | $94,648124 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $1,633 | $44,71967 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $24 | $29,19759 claims |
| AlconSimbrinza, Azopt | $863 | $15,01759 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $114 | $10,37714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 35 glaucoma specialist providers in New York.
Other glaucoma specialist in Albany
- Asher WeinerAlbany$2K
- Nalini MadiwaleAlbany$530
- Janet SerleNew York$103K
- Sarah VantasselNew York$76K
- Jonathan SchulhofBrooklyn$73K
- Sonya DharNew York$19K
- Jacqueline LenociCommack$13K
- Tak Yee Tania TaiBrooklyn$11K
- Smitha VoletiYonkers$5K
- Yvonne OkakaNew York$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.